Evidence map›Paper›PMID 40963748›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Liraz Klausner, Ateret Revital, Todd Lencz, Shai Carmi

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Liraz KlausnerBraun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Ateret RevitalBraun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Todd LenczInstitute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, New York.ORCID 0000-0001-8586-338X
Shai CarmiBraun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Funding

Polygenic Embryo Screening: Towards Informed Decision-MakingR01HG011711 · NHGRI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CARMI, SHAI, LAZARO-MUNOZ, GABRIEL · 2021 to 2025
$6.2M
NHGRI NIH HHS R01 HG011711
6 · The paper itself

Abstract

Motivation: Polygenic embryo screening (PES) is a new technology in reproductive medicine, whereby human in-vitro fertilization (IVF) embryos are screened for their genetic risk of complex, polygenic diseases. PES aims to reduce the burden of polygenic diseases in offspring by prioritizing the selection of low-risk embryos. However, given that polygenic diseases are usually late-onset, PES outcomes cannot be evaluated empirically and must be estimated by epidemiological modeling. The commonly used liability threshold model has been previously used to predict PES outcomes. However, predictions rely on complex sets of equations, some of which require numerical integration or simulation. Further, previous models failed to account for the possibility that the selected embryo will not be born. Results: Here, we present Availability and Implementation:

Identifiers

PMID40963748
PMCPMC12440052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.